Phase 3 N=11 Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.
Venous Thrombosis
Primary: Peak Anti-Xa Level — 0.35; 0.46; 0.57; 0.27 u/ml — p=0.4
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
Coronary Artery Disease
Primary: Global Hyperemic Myocardial Blood Flow (MBF) — 3.1; 3.1 mL/min/gm — p=0.14
Phase 3 N=1,564 HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents
Asthma
Primary: Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24 — 0.341; 0.377 Liters — p=0.162
Phase 2 N=20 Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy
Primary: Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. — -23; 31 Percentage change in fibrotic…
Phase 3 N=18 Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
Mucositis · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Cmax of Fentanyl — 0.67; 0.26 ng/mL
Phase 4 N=20 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
Dementia With Lewy Bodies
Primary: Mean Initial Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) — 7.0; 19.0 minutes — p=0.003
N/A N=22 Trial of Alternating Current Stimulation in Optic Neuropathy
Optic Nerve Diseases · Optic Nerve Injuries · Optic Neuropathies
Primary: Detection Accuracy (DA) Change in Percent Over Baseline Within Defective Visual Field Sectors — 24.75; 39.16 percent change
Phase 3 N=272 A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
Hepatitis C, Chronic
Primary: Percentage of Participants With at Least 1 Adverse Event — 38.2 Percentage of participants
Phase 2 N=104 Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
Malignant Glioma
Primary: 6 Month Progression-free Survival — 47.5; 71.1; 24.0 percentage of participants
N/A N=90 Effectiveness of Video System in Improving Learning of Tracheal Intubation Using Standard Laryngoscopy Among Novices
Intubation Intraesophageal
Primary: Successful Endotracheal Intubation — 33.3; 83.3 % successful — p=.001
N/A N=65 mDiet - Ecological Momentary Intervention of Diet Via Mobile Technology
Overweight
Primary: Mean Weight (kg) — 87.85; 85.17 kg
Phase 2 N=43 Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
Lymphoma
Primary: Rate of Immunological Response to Vaccination — 0; 15 participants
Phase 4 N=31 Anesthetic Effect Duration Assessment
Healthy Volunteers
Primary: Duration of Anesthesia(Minutes) — 80; 140; 0; 400 Minutes
Phase 2 N=143 An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
Multiple Sclerosis
Primary: Percentage of Patients Free of Gd-enhanced T1 Weighted Magnetic Resonance Imaging (MRI) Lesions — 88.6; 97.9; 58.0; 90.9 Percentage of patients
Phase 3 N=23,738 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) — 240; 304 Subjects